Press Releases

Pancreatic ductal adenocarcinoma (PDAC), while not among the most common cancers, remains one of the deadliest and most treatment-resistant tumors, with a five-year survival rate of just 10 –11%. Despite the introduction of new treatment options, the standard of care has seen little progress over the past three decades, and overall survival still ranges between 6 and 12 months. This poor prognosis is largely due to the tumor’s inherent resistance to chemotherapy and radiotherapy, driven in part by cancer stem cells (CSCs) with unique transcriptional profiles regulated by epigenetic and epitranscriptomic mechanisms. The Fraunhofer Institute for Biomedical Engineering IBMT with its expertise in the development of customized nanoparticles is part of the international consortium.